2025 · 3rd Quarter (July 1 - Sep 30)

NOVO NORDISK, INC.

Filed by THE NICKLES GROUP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 16, 2025
Income: $80,000.00
Expenses: Not reported
Registrant: THE NICKLES GROUP, LLC
Client: NOVO NORDISK, INC.
Filing UUID: fb149e56-a4d7-4565-87d0-d2ba93bdafb5
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to compounding and counterfeit drugs.

MMM · Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Literal federal measure citations: H.R. 1492, H.R. 1

TAX · Taxation/Internal Revenue Code

H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Literal federal measure citations: H.R. 1, H.R. 591, H.R. 2423

TRD · Trade (domestic/foreign)

Issues related to tariffs. Issues related to importation of counterfeit drugs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.